Drug class: Alpha blockers
- Tamsulosin with a low propensity for side effects, is relatively selective for α1A and D-adrenoceptors over α1B-adrenoceptors.
- The long-term efficacy and safety of tamsulosin in BPH (benign prostatic hyperplasia), evident from previous shorter-term and 4-year long-term clinical trials are proven.
- This α1A subtype selective adrenergic receptor blocker is a viable long-term alternative to surgery.
Drug class: 5-alpha reductase inhibitors
- Dutasteride is the first dual inhibitor of both 5α reductase isoenzymes.
- Improves urinary symptoms and flow rate.
- Also associated with significant improvements in BPH Impact Index (BII) score, reflecting improvements in quality of life for men with BPH.
- Advantageous in the chemoprevention of prostate cancer
- Combination therapy with dutasteride and tamsulosin was significantly superior to both monotherapies at reducing the relative risk of BPH clinical progression.
- Combination therapy was significantly superior to tamsulosin monotherapy (but not dutasteride monotherapy) at reducing the relative risk of AUR (acute urinary retention) or BPH-related surgery.
- Safety and tolerability of combination therapy was consistent with previous experience with dutasteride and tamsulosin monotherapies.
- Combined therapy with dutasteride plus tamsulosin provided better long-term (up to 4years) control of both storage and voiding LUTS compared with tamsulosin monotherapy.